In melanoma, activating Rac1 mutations appear not to function as primary driver mutations; however, they may cooperate with driver mutations to promote melanoma cell proliferation, tumor progression, and metastasis, resistance to targeted therapy, and worse patient outcomes [6, 9, 12, 13]. Here, RAC1 is linked to neoplasm.